Company news
Invivyd, Inc. (NASDAQ:IVVD) news
Invivyd, Inc. news releases on 6ix. Latest, Oct 5, 2026: Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 4, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
September 29, 2026
Invivyd to Participate in Upcoming September Investor Conferences
September 8, 2026
Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
September 4, 2026
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
September 1, 2026
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 4, 2026
August 5, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 4, 2026
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 6, 2026
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
June 16, 2026
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Adminis...
June 8, 2026
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
May 31, 2026
Invivyd to Participate in Upcoming Investor Events
May 26, 2026
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
May 7, 2026
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
April 20, 2026
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
April 8, 2026
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
April 6, 2026
Invivyd Announces Presentation at the World Vaccine Congress Washington
March 29, 2026
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
March 4, 2026
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
March 4, 2026
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
March 2, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2026
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
February 24, 2026
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
January 22, 2026
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
January 20, 2026
Adimab Records Another Year of Double-Digit Clinical Program Growth
January 13, 2026
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
January 8, 2026
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
December 23, 2025
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
December 23, 2025
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
November 25, 2025
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
November 24, 2025
Invivyd Announces Proposed Public Offering of Common Stock
November 17, 2025
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
November 16, 2025
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
November 3, 2025
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
October 28, 2025
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
October 6, 2025
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
September 24, 2025
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
September 17, 2025
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
September 4, 2025
Invivyd to Participate in Upcoming Investor Conferences
August 27, 2025
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
August 22, 2025
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
August 19, 2025
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
August 18, 2025
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 14, 2025
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
August 14, 2025
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
July 23, 2025